Straining the system: Schafer and Grosvenor in MedAd News

As more gene and CAR-T therapies enter the market, especially in therapeutic categories with more patients such as cancer, experts say manufacturers will have to up their game in establishing the true value of their therapies, and work closely with payers on payment agreements. Precision for Value experts Jeremy Schafer and Alex Grosvenor offer their perspectives in this MedAd News cover story.

To read the full article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.